Signant Health has acquired Ametris, formerly known as ActiGraph, in a move designed to combine wearable-based digital measurements with electronic clinical outcome assessment (eCOA) technology. Financial terms of the acquisition were not disclosed.
The transaction reflects increasing demand among pharmaceutical sponsors for more integrated evidence generation platforms that combine patient-reported experiences with objective physiological data. By consolidating these capabilities into a single platform, the companies aim to reduce operational complexity associated with managing multiple technology vendors during clinical trials.
Signant Health currently works with more than 600 sponsors and contract research organizations, including all of the top 20 pharmaceutical companies. Ametris brings two decades of experience in regulatory-aligned wearable measurement systems, particularly in collecting continuous real-world patient data outside traditional clinical settings.
Roger Smith, CEO of Signant Health, said the acquisition represents a commitment to advancing clinical evidence generation through a unified workflow for sponsors. Jeremy Wyatt, CEO of Ametris, noted that the combination will accelerate the development of integrated evidence systems while simplifying vendor management for pharmaceutical companies.
The combined offering is expected to support decentralized and hybrid clinical trial models by enabling remote data collection from participants in real-world environments. The integrated system will combine subjective patient feedback gathered through eCOA tools with objective sensor-based measurements generated by wearable devices.
This multimodal approach is viewed as increasingly important in therapeutic areas such as Central Nervous System (CNS) disorders, where regulators often require multiple forms of evidence to validate treatment benefits. The integration is intended to help sponsors build richer longitudinal datasets that capture both symptom reporting and physiological indicators over time.
Near-term plans for the merger include unified workflows and integrated analytics capabilities. Longer term, the companies plan to develop what they describe as a Medical Intelligence Layer that incorporates artificial intelligence and machine learning technologies.
These future capabilities may support the identification of patterns across patient-reported and sensor-derived datasets, potentially enabling composite outcome measures and real-time clinical trial monitoring. Such applications are drawing increasing attention from both regulators and drug developers seeking more efficient and data-driven approaches to evidence generation.
Click here for the original news story.
